Volition Launches NuQ® Epigenetic Immunoassays for Research Use
VolitionRX to Begin Prospective Clinical Trial in Colon Cancer
VolitionRX Issues CEO Letter to Shareholders
VolitionRX Signs Collaboration Agreement With Stefan Holdenrieder of Rheinische Friedrich-Wilhelms-Universitat Bonn Germany
VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests
Pioneering New Science Nucleosomics Advances Blood Based Diagnostics for Cancer
Volition Signs Collaboration Agreement With Abcodia
VolitionRX Limited Intellectual Property Update: New Patent Filed
VolitionRX Limited Issues 525,000 Shares to ValiRx; Final Requirement of Share Purchase Agreement
Volition Ticker Symbol Changed to VNRX.OB; Name Change to VolitionRX Limited Completed